NCT04789668: Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases

Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least one measurable untreated brain lesion greater than or equal to 0.5 cm & less than 3.0 cm; Prior stereotactic radiosurgery (SRS) with up to 3 lesions treated with at least a 14 day interval is allowed as long as the previous treatment volume does not overlap with the current targets
Exclusions: Patients with clinical or radiographic evidence of leptomeningeal disease; Patients with prior whole brain radiotherapy (WBRT)

Comments are closed.

Up ↑